Understanding OUR Cytokine-Based Immunotherapy Candidates Our motivation extends to advancing a robust portfolio of programs directed at growing the horizons of cytokine-based immunotherapy, specifically for cancers where cure selections remain limited. Utilize the links below to learn much more about our portfolio of cytokine-based immunotherapy candidates. Discover Our Pipeline https://financefeeds.com/equilend-appoints-fintech-expert-nick-delikaris-as-chief-product-officer/